Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase

A stratified medicine approach for the treatment of psoriasis promises greater certainty of clinical decision making through prediction of response on the basis of clinical, pharmacological, and omics data from an individual patient. As yet, there is no predictive model for treatment response in routine clinical use for psoriasis. The Psoriasis Stratification to Optimise Relevant Therapy (PSORT) Consortium is a United Kingdom Medical Research Council.funded, academic.industrial stratified medicine consortium established with the objective of discovering the predictors and stratifiers of response of psoriasis to biologic therapies. A showcase meeting was convened and attended by 80 stakeholders at the Royal College of Physicians, London, United Kingdom on 18 November 2019. The purpose was to disseminate the research findings from the PSORT consortium discovered thus far. This report summarizes the presentations made on the day and the significant advances made by PSORT toward a stratified medicine approach to the management of psoriasis.

Automated summary

A stratified medicine approach for psoriasis treatment aims to improve clinical decision-making by predicting individual patient response based on clinical, pharmacological, and omics data. The PSORT Consortium, funded by the UK Medical Research Council, focuses on discovering predictors and stratifiers of psoriasis response to biologic therapies. A showcase meeting in London in November 2019 highlighted the research findings and significant advances made by PSORT towards personalized management of psoriasis.